GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PhotoCure ASA (OSL:PHO) » Definitions » Institutional Ownership

PhotoCure ASA (OSL:PHO) Institutional Ownership : 23.29% (As of Dec. 16, 2024)


View and export this data going back to 2000. Start your Free Trial

What is PhotoCure ASA Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PhotoCure ASA's institutional ownership is 23.29%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PhotoCure ASA's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PhotoCure ASA's Float Percentage Of Total Shares Outstanding is 0.00%.


PhotoCure ASA Institutional Ownership Historical Data

The historical data trend for PhotoCure ASA's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhotoCure ASA Institutional Ownership Chart

PhotoCure ASA Historical Data

The historical data trend for PhotoCure ASA can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 23.61 23.91 24.11 24.35 23.94 24.12 23.46 23.36 23.31 23.29

PhotoCure ASA Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


PhotoCure ASA Business Description

Traded in Other Exchanges
Address
Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products specialty pharmaceutical companies. Its technology platform is focused on the field of photodynamic diagnosis and treatment of cancer. It has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, and the United States.

PhotoCure ASA Headlines